Sandeep Vijan, MD, MS; Rodney A. Hayward, MD
Cardiovascular disease is the primary complication and cause of death in patients with type 2 diabetes mellitus. Modification of cardiovascular risk factors may improve patient outcomes.
To evaluate the effectiveness of pharmacologic lipid-lowering therapy on outcomes in type 2 diabetes mellitus.
Review of the literature.
Randomized trials evaluating clinical outcomes of lipid-lowering treatment in patients with diabetes.
Studies were identified by searching the Cochrane Library, MEDLINE, meta-analyses, review articles, and inquiries to experts. The Cochrane Library and MEDLINE searches were done in September 2002. Data were abstracted onto standardized forms by a single reviewer and were confirmed by a second reviewer.
Meta-analysis of 6 primary prevention studies showed that lipid-lowering medications reduced risks for cardiovascular outcomes (relative risk, 0.78 [95% CI, 0.67 to 0.89]; absolute risk reduction, 0.03 [CI, 0.01 to 0.04] in 4.3 years of treatment); 1 major cardiovascular event was prevented by treating 34 to 35 patients. Meta-analysis of 8 studies of secondary prevention showed a similar relative risk (0.76 [CI, 0.59 to 0.93]) but more than twice the absolute risk reduction (0.07 [CI, 0.03 to 0.12] in 4.9 years of treatment) and a number needed to treat for benefit of 13 to 14. Most studies compared a lipid-lowering drug with placebo but did not evaluate the effect of reaching specific cholesterol levels. The benefit of lipid lowering with a fixed dose of a statin appeared to be similar regardless of starting cholesterol levels.
Target cholesterol levels and the effectiveness of dose titration (or the use of multiple agents) have not been rigorously examined.
In patients with type 2 diabetes, treatment with lipid-lowering agents reduces cardiovascular risk. Most patients, including those whose baseline low-density lipoprotein cholesterol levels are below 2.97 mmol/L (<115 mg/dL), and possibly below 2.59 mmol/L (<100 mg/dL), benefit from statins. Moderate doses of these drugs suffice in most patients with diabetes.
Note that the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is not included in this figure because data on absolute risk reduction in the diabetes subgroup were not available. AFCAPS/TexCAPS = Air Force Coronary Atherosclerosis Prevention Study/Texas Coronary Atherosclerosis Prevention Study; ASCOT-LLA = Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm; HHS = Helsinki Heart Study; HPS-1 = Heart Protection Study (primary prevention arm); PROSPER-1 = Prospective Study of Pravastatin in the Elderly at Risk (primary prevention arm).
The meta-analysis was done by using a random-effects model because of between-study heterogeneity ( = 0.026). 4S = Scandinavian Simvastatin Survival Study; CARE = Cholesterol and Recurrent Events trial; HPS-2 = Heart Protection Study (secondary prevention arm); LIPID = Long-term Intervention with Pravastatin in Ischemic Disease trial; LIPS = Lescol Intervention Prevention Study; Post-CABG = Post–Coronary Artery Bypass Graft trial; PROSPER-2 = Prospective Study of Pravastatin in the Elderly at Risk (secondary prevention arm); VA-HIT = Veterans Administration High-Density Lipoprotein Cholesterol Intervention Trial.
Vijan S, Hayward RA. Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians. Ann Intern Med. 2004;140:650–658. doi: https://doi.org/10.7326/0003-4819-140-8-200404200-00013
Download citation file:
Published: Ann Intern Med. 2004;140(8):650-658.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use